

WHAT IS CLAIMED IS:

1 1. A method for inhibiting a condition characterized by monocytic
2 infiltrates, wherein said method comprises administering to a patient a therapeutically
3 effective amount of an MCP-1 receptor antagonist in a suitable pharmaceutical carrier,
4 wherein said MCP-1 receptor antagonist binds to an MCP-1 receptor polypeptide.

1 2. The method of claim 1, wherein said MCP-1 receptor polypeptide
2 comprises the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.

1 3. The method of claim 1, wherein said MCP-1 receptor antagonist is
2 administered to said patient as a pharmaceutical composition.

1 4. The method of claim 3, wherein said pharmaceutical composition
2 contains about 10 µg/ml to about 1 mg/ml of the antagonist.

1 5. The method of claim 1, wherein said antagonist is an antibody or
2 binding fragment thereof.

1 6. The method of claim 5, wherein said antibody or binding fragment
2 thereof is administered to said patient as a pharmaceutical composition.

1 7. The method of claim 5, wherein said antibody is a monoclonal
2 antibody.

1 8. The method of claim 5, wherein said antibody is a humanized
2 antibody.

1 9. The method of claim 1, wherein said condition is atherosclerosis.

1 10. A method for inhibiting MCP-1 receptor polypeptide, wherein said
2 method comprises administering to a patient a therapeutically effective amount of an MCP-1
3 receptor antagonist in a suitable pharmaceutical carrier, wherein said MCP-1 receptor
4 antagonist binds to said MCP-1 receptor polypeptide.

1 11. The method of claim 10, wherein said MCP-1 receptor polypeptide
2 comprises the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.

1 12. The method of claim 10, wherein said MCP-1 receptor antagonist is
2 administered to said patient as a pharmaceutical composition.

1 13. The method of claim 12, wherein said pharmaceutical composition
2 contains about 10 $\mu\text{g/ml}$ to about 1 mg/ml of the antagonist.

1 14. The method of claim 10, wherein said antagonist is an antibody or
2 binding fragment thereof.

1 15. The method of claim 14, wherein said antibody or binding fragment
2 thereof is administered to said patient as a pharmaceutical composition.

1 16. The method of claim 14, wherein said antibody is a monoclonal
2 antibody.

1 17. The method of claim 14, wherein said antibody is a humanized
2 antibody.